Compare Biogen Inc (BIIB) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs EHang Holdings Ltd - ADR — how do they compare? Biogen Inc trades at $207.27 (market cap $30.13B), while EHang Holdings Ltd - ADR trades at $5.68 (market cap $437.63M). The key difference: Biogen Inc is far larger — about 68.8× EHang Holdings Ltd - ADR's market cap, and Biogen Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| BIIB | EH | |
|---|---|---|
Market Cap | $30.13B | $437.63M |
Sector | Health | Industrials |
52-Week High | $216.63 | $19.44 |
52-Week Low | $128.93 | $4.90 |
Enterprise Value | $37.20B | $376.84M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
EHang Holdings (EH) trades at $5.66, down 0.53% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, but net losses persist with a margin of -77.57%. Recent news includes the successful pilotless eVTOL flight in Kazakhstan, highlighting operational progress amid financial challenges.
The stock presents high-risk potential with analyst consensus divided and a price target of $6.97. Investment appeal hinges on commercialization success and cost management, but substantial losses and competitive pressures pose significant risks to near-term shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
